Summary

for males ages 18-65 (full criteria)
at UCLA
study started
Other James Peck (ucla)

Description

Summary

The purpose of this study is...to assess whether placing a substance abuse intervention for HIV+ methamphetamine users within an HIV medical care setting improves rates of follow-up on referral to treatment by primary care physicians; reduces drug use and sexual risk behaviors more than treatment-as-usual; and increases rates of adherence to HIV medication regimens.

Official Title

Behavioral Therapy Development for Methamphetamine Abuse

Keywords

The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings Behavior Therapy methamphetamine

Eligibility

You can join if…

Open to males ages 18-65

  1. HIV-seropositive, GBM receiving medical treatment for HIV for at least 30 days prior to signing informed consent at the UCLA CARE clinic, aged 18-65
  2. Willing to give informed consent and comply with study procedures;
  3. Willing to provide consent to contact treating physicians and pharmacies to assess adherence to HIV medications;
  4. Diagnosed with current methamphetamine abuse as determined by MINI; and
  5. Interested in seeking treatment for their methamphetamine abuse and in participating in this research project.

You CAN'T join if...

  1. Unwilling to give, or withdrawal of, informed consent;
  2. Inability to understand nature of study;
  3. A psychiatric condition that, in the principal investigator's judgment, warrants additional intervention to ensure participant safety (e.g., meets DSM-IV-TR criteria for current bipolar disorder or a psychotic disorder);
  4. Current suicidal ideation or suicide attempt within the past 3 months; and
  5. Concurrent dependence on opiates, alcohol, or benzodiazepines as determined by MINI.
  6. Total lack of any type of healthcare coverage. These potential participants will be given low-fee treatment referrals.

Locations

  • UCLA Medical Center
    Los Angeles California 90024 United States
  • UCLA, Integrated Substance Abuse Programs
    Los Angeles California 90024 United States
  • UCLA CARE Clinic
    Los Angeles California 90035 United States

Lead Scientist

Details

Status
currently not accepting new patients, but might later
Start Date
Sponsor
University of California, Los Angeles
ID
NCT00249678
Phase
Phase 2
Study Type
Interventional
Last Updated